Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€28.41

€28.41

1.240%
0.35
1.240%
€47.50
 
01.03.24 / Tradegate WKN: BAY001 / Symbol: BAYZF / Name: Bayer / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Bayer AG Stock

There is an upward development for Bayer AG compared to yesterday, with an increase of €0.35 (1.240%).
With 19 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 47 € shows a very positive potential of 65.46% compared to the current price of 28.41 € for Bayer AG.
For the coming years our community has positive and negative things to say abot the Bayer AG stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.

Bayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.

Pros and Cons of Bayer AG in the next few years

Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Bayer AG vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Bayer AG 1.240% -2.494% -8.530% -49.884% -16.345% -44.346% -60.099%
Merck KGaA -0.440% 0.477% 2.629% -11.725% 9.830% 17.198% 72.749%
Pfizer Inc. -0.610% -3.340% -3.150% -35.871% -5.747% -11.367% -31.767%
Elanco Animal Health Inc. 0.410% -1.606% 5.000% 35.484% 8.728% -46.025% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-20

From an initial glance at the financials of Bayer (BAYZF), it's evident that the company has a significant market presence in the pharmaceuticals industry, boasting a diverse asset portfolio and robust revenues. However, while the company exhibits resilience and growth potential, it also faces notable challenges, particularly in areas such as debt, net income fluctuations, and operational expenditures.

Revenue growth: Bayer has shown a consistent increase in total revenue over the past three years, from €41.4 billion in 2020 to €44.08 billion in 2021, and €50.74 billion in 2022. This trend indicates that the company is maintaining strong market performance, with potential for further revenue growth.

Asset base: Bayer has a substantial asset base, with the total assets increasing from €117.05 billion in 2020 to €120.24 billion in 2021, and finally to €124.88 billion in 2022. This growth demonstrates the company's ability to effectively manage and expand its operations.

Comments

Prediction Buy
Perf. (%) 3.91%
Target price 60.000
Change
Ends at 13.08.23

Target price set to 60.0
Show more

Buy Bayer AG
Show more

Prediction Buy
Perf. (%) 5.75%
Target price 60.000
Change
Ends at 09.03.23

Target price changed to 60.0
Show more

News

EQS-Adhoc: Bayer Aktiengesellschaft: Bayer plans to amend its dividend policy to reduce debt: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24691/Logo_der_Bayer_AG.svg.png
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer plans to amend its dividend policy to reduce debt
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer plans to amend its dividend policy to reduce debt
EQS-Adhoc: Bayer Aktiengesellschaft: OCEANIC-AF study stopped early due to lack of efficacy: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24691/Logo_der_Bayer_AG.svg.png
EQS-Adhoc: Bayer Aktiengesellschaft: OCEANIC-AF study stopped early due to lack of efficacy
EQS-Adhoc: Bayer Aktiengesellschaft: OCEANIC-AF study stopped early due to lack of efficacy
Agriculture Titans Are In a Head-to-Head Battle for America's Soy Farmers: https://g.foolcdn.com/editorial/images/747968/featured-daily-upside-image.jpeg
Agriculture Titans Are In a Head-to-Head Battle for America's Soy Farmers

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

The US harvests